Search tips
Search criteria 


Logo of ccforumBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleCritical CareJournal Front Page
Crit Care. 2007; 11(6): 183.
Published online 2007 December 28. doi:  10.1186/cc6193
PMCID: PMC2246224

RAGE: Exacting a toll on the host in response to polymicrobial sepsis and Listeria monocytogenes


The receptor for advanced glycation endproducts (RAGE) has complex roles in the immune/inflammatory response. RAGE is expressed on monocytes/macrophages, T and B lymphocytes, and dendritic cells. Previous studies illustrated that homozygous RAGE-/- mice subjected to overwhelming bacterial sepsis displayed normal clearance of pathogenic bacteria and significantly increased survival. In this issue of Critical Care, Lutterloh and colleagues confirm these findings and provide evidence that blocking antibodies to RAGE afford similar protection in mice, even when administration of anti-RAGE is delayed by 24 hours. Furthermore, these authors illustrate that deletion of RAGE is remarkably protective in mice infected with the intracellular pathogen Listeria monocytogenes. In this Commentary, we consider these findings and propose possible mechanisms by which RAGE exacts a heavy toll on the host in response to polymicrobial sepsis and L. monocytogenes.

The receptor for advanced glycation endproducts (RAGE) plays central roles in the immune/inflammatory response. In this issue of Critical Care, Lutterloh and colleagues [1] tested roles for RAGE in two distinct models of severe infection in mice: (a) that induced by cecal ligation and puncture and (b) overwhelming infection with Listeria monocytogenes. RAGE is a multi-ligand receptor that binds fundamental regulatory molecules of inflammatory responses, the S100/calgranulins and high-mobility group box-1 (HMGB-1). The beneficial effects of ligand-RAGE blockade were observed in delayed-type hypersensitivity reactions, collagen-induced arthritis, experimental autoimmune encephalomyelitis, and alloimmunity, for example [2]. RAGE is expressed by multiple cell types implicated in the immune/inflammatory response, such as monocytes/macrophages, T and B lymphocytes, and dendritic cells. Ligand-RAGE interaction activates monocytes/macrophages, and recent studies provide compelling evidence for the role of RAGE in effective T-lymphocyte priming. In vivo and in vitro, T lymphocytes devoid of RAGE display markedly reduced proliferative and cytokine responses (interferon-γ and interleukin-2) to nominal or alloantigen [3]. Lutterloh and colleagues show that RAGE is not essential for clearance of pathogenic bacteria in polymicrobial sepsis or to L. monocytogenes. Rather, they illustrate that deletion of RAGE enhances survival compared with wild-type mice. How may we explain these findings?

In confirming the results of others in RAGE-/- mice [4], these authors showed that homozygous or heterozygous deletion of the RAGE gene was strongly protective in mice subjected to cecal ligation and puncture. Furthermore, administration of blocking monoclonal antibodies to RAGE, even when delayed by 24 hours, afforded survival benefit in mice subjected to this procedure. These data provide compelling evidence that RAGE is not required for fundamental innate responses that clear bacteria. Rather, RAGE may mediate hyperinflammatory responses to the invading bacteria that are injurious to the host. Clues that this is a likely explanation have come from the novel findings of Lutterloh and colleagues in L. monocytogenes-challenged RAGE-/- mice.

These authors challenged mice with L. monocytogenes and report that RAGE-/- mice or RAGE+/- mice displayed an LD50 (median lethal dose) that was more than two orders of magnitude higher than that of wild-type mice. In BALB/c mice, administration of anti-RAGE antibody offered significant protection against listeriosis. Importantly, bacterial counts did not differ among RAGE-/- and antibody-treated mice compared with controls.

As recently reviewed by Pamer [5], in the first few days of Listeria infection, the innate response is critical for early bacterial clearance and host survival. The adaptive response instead is required for controlling chronic, but not acute, infection since SCID (severe combined immunodeficiency disease) mice survive early listeriosis normally, but ultimately this infection is lethal due to long-term failure to clear the organism [6,7]. In the initial phase of infection, Listeria binds to splenic macrophages and is internalized; Listeria produces products that activate nuclear factor-kappa B and upregulate innate immune molecules such as CC-chemokine ligand CCL2 [5]. Infected macrophages then release microbial products and engage Toll-like receptors (TLRs). Via myeloid differentiation factor 88 (Myd88), these macrophages differentiate into TNF (tumor necrosis factor)- and iNOS (inducible nitric oxide synthase)-producing cells that directly promote bacterial killing. Innate immune responses are thoroughly essential for host survival to Listeria as mice deficient in Myd88 are exquisitely vulnerable to this bacterium [8]. Interestingly, mice deficient in either TLR-2 or TLR-4 display relatively normal resistance to Listeria [8,9], suggesting that compensation by other TLRs may override the loss of a single TLR and permit macrophage activation and bacterial killing. Unlike the TLRs, RAGE is not likely to be activated directly by microbial products. However, RAGE ligands inducibly expressed upon macrophage activation may potentiate initial innate activation and the systemic inflammatory response.

It is well established that in listeriosis, production of interferon-γ presumably by natural killer cells or T lymphocytes is critical for macrophage activation and initial bacterial clearance as well as for promotion of long-term protective cellular immunity [10]. Herein lies an intriguing piece of the puzzle; RAGE-/- mice displayed strikingly decreased levels of interferon-γ compared with wild-type mice in listeriosis yet were significantly protected from the injurious effects of the microorganism. In addition to revealing that production of this cytokine is not absolutely linked to the initial clearance of L. monocytogenes, these findings are consistent with the notion that the RAGE-induced proinflammatory state may be deleterious in the early stages of infection yet may ultimately promote protective adaptive Th1 cellular immunity. Thus, we may predict that deletion of RAGE or RAGE blockade suppresses interferon-γ-propagated macrophage activation and the hyperinflammation response that injures the host. However, since RAGE is critical for the Th1 adaptive response [3], it will be important to address the effect of RAGE deficiency or blockade on long-term anti-Listeria immunity. Note that Lutterloh and colleagues examined interferon-γ levels at 48 hours post-infection and in plasma only, not tissue. Thus, it remains possible that levels of this cytokine in RAGE-/- mice might have been different at distinct sites or time points in the infection.

How may RAGE signaling pathways be specifically recruited in listeriosis? Adaptive RAGE-dependent mechanisms may contribute to production of interferon-γ. What, then, overrides the otherwise protective effects of interferon-γ production? We propose that stimulated macrophages, in addition to releasing microbial products in the early response to infection [11], release the RAGE ligand HMGB-1 [12,13]. HMGB-1, which may engage TLR-2 and TLR-4 [14], as well as RAGE, might activate signaling systems that stimulate hyperinflammatory responses (Figure (Figure11).

Figure 1
Proposed model of how the receptor for advanced glycation end products (RAGE) mediates tissue injury in listeriosis. Lutterloh and colleagues [1] show that in polymicrobial gut sepsis and in mice infected with Listeria monocytogenes, RAGE is not essential ...

In conclusion, in polymicrobial sepsis and in response to L. monocytogenes, genetic deletion of RAGE is remarkably protective. RAGE is not directly required for bacterial clearance, but the compelling experiments of Lutterloh and colleagues confirm that RAGE action mediates tissue damage initiated in response to overwhelming bacterial infection. Future studies must dissect the precise mechanisms by which RAGE exacts a heavy toll on the host during efforts to combat pathogenic bacteria.


HMGB-1 = high-mobility group box-1; Myd88 = myeloid differentiation factor 88; RAGE = receptor for advanced glycation end products.

Competing interests

AMS receives research support from TransTech Pharma, Inc. and is a member of their Scientific Advisory Board.


The authors gratefully acknowledge the support of the Juvenile Diabetes Research Foundation and the US Public Health Service.


See related research by Lutterloh et al.,


  • Lutterloh EC, Opal SM, Pittman DD, Keith JC, Jr, Tan X-Y, Clancy BM, Palmer H, Milarski K, Sun Y, Palardy JE, et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care. 2007;11:R122. doi: 10.1186/cc6184. [PMC free article] [PubMed] [Cross Ref]
  • Herold K, Moser B, Chen Y, Zeng S, Yan SF, Ramasamy R, Emond J, Clynes R, Schmidt AM. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J Leukoc Biol. 2007;82:204–212. doi: 10.1189/jlb.1206751. [PubMed] [Cross Ref]
  • Moser B, Desai DD, Downey M, Chen Y, Yan SF, Herold K, Schmidt AM, Clynes R. RAGE expression on T cells contributes to antigen-specific cellular expansion in vivo. J Immunol. 2007;179:8051–8058. [PubMed]
  • Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, Plachky J, Gröne H-J, Kurschus FC, Schmidt AM, et al. Receptor for advanced glycation endproducts (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest. 2004;113:1641–1650. doi: 10.1172/JCI200418704. [PMC free article] [PubMed] [Cross Ref]
  • Pamer EG. Immune responses to Listeria monocytogenes. Nat Rev Immunol. 2004;4:812–823. doi: 10.1038/nri1461. [PubMed] [Cross Ref]
  • Deschryver-Kecskemeti K, Bancroft GJ, Bosma GC, Bosma MJ, Unanue ER. Pathology of Listeria infection in murine severe combined immunodeficiency. A study by immunohistochemistry and electron microscopy. Lab Invest. 1988;58:698–705. [PubMed]
  • Bancroft GJ, Schreiber RD, Unanue ER. Natural immunity: a T-cell-independent pathway of macrophage activation, defined in the scid mouse. Immunol Rev. 1991;124:5–24. doi: 10.1111/j.1600-065X.1991.tb00613.x. [PubMed] [Cross Ref]
  • Seki E, Tsutsui H, Tsuji NM, Hayashi N, Adachi K, Nakano H, Futatsugi-Yumikura S, Takeuchi O, Hoshino K, Akira S, et al. Critical roles of myeloid differentiation factor 88-dependent proinflammatory cytokine release in early phase clearance of Listeria monocytogenes in mice. J Immunol. 2002;169:3863–3868. [PubMed]
  • Edelson BT, Unanue ER. MyD88-dependent but toll-like receptor-2 independent innate immunity to Listeria: no role for either in macrophage listericidal activity. J Immunol. 2002;169:3869–3875. [PubMed]
  • Harty JT, Bevan MJ. Specific immunity to Listeria monocytogenes in the absence of IFN-γ Immunity. 1995;3:109–117. doi: 10.1016/1074-7613(95)90163-9. [PubMed] [Cross Ref]
  • Vazquez MA, Sicher SC, Wright WJ, Proctor ML, Schmalzried SR, Stallworth KR, Crowley JC, Lu CY. Differential regulation of TNF-alpha production by listeriolysin-producing versus non-producing strains of Listeria monocytogenes. J Leukoc Biol. 1995;58:556–562. [PubMed]
  • Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, et al. Blockade of RAGE-amphoterin signaling suppresses tumour growth and metastases. Nature. 2000;405:354–360. doi: 10.1038/35012626. [PubMed] [Cross Ref]
  • Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248–251. doi: 10.1126/science.285.5425.248. [PubMed] [Cross Ref]
  • Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004;279:7370–7377. doi: 10.1074/jbc.M306793200. [PubMed] [Cross Ref]

Articles from Critical Care are provided here courtesy of BioMed Central